Skip to main content
Premium Trial:

Request an Annual Quote

Merrimack Gets NCI Phase I SBIR Grant for Protein Microarrays

NEW YORK, Jan. 29 (GenomeWeb News) - Merrimack Pharmaceuticals has received a Phase I SBIR Grant from the National Cancer Institute, the company said today.

 

Merrimack said it will use the grant, "Protein Microarrays in Cancer Drug Discovery," to develop and apply its microarray technology to apoptosis and cancer.

 

"The protein microarray research in this grant, combined with Merrimack's expertise in computational modeling and high-throughtput biology, should yield tremendous results in this difficult field," Michael Cardone, the company's director of science development, said in a statement.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.